The share is meeting an important level. We suggest caution because this point could stop the bullish trend.
From a fundamental viewpoint, the company is expected to lose money in 2014. Indeed the expected EPS should represent a loss of $0.40. Moreover, the company seems to be over-valuated with a P/E ratio of 50.7 on 2015 estimates.
From a technical viewpoint, the proximity of the USD 108.3 medium and long-term resistance limits the upside potential on the stock. The uptrend in the short term could be stopped by this level and prices could decrease sharply in the coming sessions. Technical indicators also show an overbought situation that reinforces this bearish scenario.
The graphical configuration argues to establish a short position at the current price. The end of the technical rebound, the consolidation phase and overbought situation: Pacira Pharmaceuticals has all the characteristics for short selling. The first objective will be fixed near the USD 95.10 short term support. This strategy should be protected by a stop loss above USD 108.30.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
PACIRA BIOSCIENCES, INC. 
